IBDEI0UN ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15115,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,15115,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,15115,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,15116,0)
 ;;=451.9^^89^902^121
 ;;^UTILITY(U,$J,358.3,15116,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15116,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,15116,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,15116,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,15117,0)
 ;;=446.6^^89^902^122
 ;;^UTILITY(U,$J,358.3,15117,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15117,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,15117,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,15117,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,15118,0)
 ;;=286.4^^89^902^125
 ;;^UTILITY(U,$J,358.3,15118,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15118,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,15118,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,15118,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,15119,0)
 ;;=204.00^^89^902^1
 ;;^UTILITY(U,$J,358.3,15119,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15119,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,15119,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,15119,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,15120,0)
 ;;=204.01^^89^902^3
 ;;^UTILITY(U,$J,358.3,15120,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15120,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,15120,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,15120,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,15121,0)
 ;;=204.10^^89^902^16
 ;;^UTILITY(U,$J,358.3,15121,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15121,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,15121,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,15121,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,15122,0)
 ;;=204.11^^89^902^18
 ;;^UTILITY(U,$J,358.3,15122,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15122,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,15122,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,15122,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,15123,0)
 ;;=201.90^^89^902^83
 ;;^UTILITY(U,$J,358.3,15123,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15123,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,15123,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,15123,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,15124,0)
 ;;=785.6^^89^902^89
 ;;^UTILITY(U,$J,358.3,15124,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15124,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,15124,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,15124,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,15125,0)
 ;;=200.20^^89^902^90
 ;;^UTILITY(U,$J,358.3,15125,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15125,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,15125,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,15125,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,15126,0)
 ;;=202.00^^89^902^92
 ;;^UTILITY(U,$J,358.3,15126,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15126,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,15126,1,5,0)
 ;;=5^Lymphoma,Low-Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,15126,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,15127,0)
 ;;=200.10^^89^902^91
 ;;^UTILITY(U,$J,358.3,15127,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15127,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,15127,1,5,0)
 ;;=5^Lymphoma,Int or High Grade,Site Unspec
 ;;^UTILITY(U,$J,358.3,15127,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,15128,0)
 ;;=273.3^^89^902^93
 ;;^UTILITY(U,$J,358.3,15128,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15128,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,15128,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,15128,2)
 ;;=^73013
